The Conversation (0)
Vaxil Granted First U.S. Patent for Its Cancer Immunotherapy Antibody Platform
Mar. 01, 2018 09:09AM PST
Genetics Investing
VAXIL BIO (TSXV: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has successfully obtained a U.S. Patent for its Signal Peptide Antibody Platform known as SPmAb™. As quoted in the press release: “Although this marks Vaxil’s 8th granted patent, we are pleased to finally have the first patent specifically …
VAXIL BIO (TSXV: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has successfully obtained a U.S. Patent for its Signal Peptide Antibody Platform known as SPmAb™.
As quoted in the press release:
“Although this marks Vaxil’s 8th granted patent, we are pleased to finally have the first patent specifically protecting the Company’s proprietary antibody platform known as SPmAb™,” Vaxil CEO Mr. Isaac Maresky commented. “Our research and development to date has indicated that this family of antibodies possess both therapeutic and diagnostic potential for cancer patients.”